PREVICOX 227 MG VETERINARY

Țară: Israel

Limbă: engleză

Sursă: Ministry of Health

Cumpara asta acum

Descarcare Prospect (PIL)
20-12-2021

Ingredient activ:

FIROCOXIB

Disponibil de la:

BEIT-EREZ HAVAT MILATIN LTD

Forma farmaceutică:

CHEWABLE TABLETS

Compoziție:

FIROCOXIB 227 MG

Calea de administrare:

PER OS

Tip de prescriptie medicala:

Required

Produs de:

BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY

Indicații terapeutice:

For the relief of pain and inflammation associated with osteoarthritis in dogs.For the relief of post-operative pain and inflammation associated with soft-tissue surgery in dogs.For the relief of post-operative pain and inflammation associated with orthopaedic and dental surgery in dogs.

Data de autorizare:

2015-10-31

Prospect

                                وأ ىقلتي بلكلا ناك اذإ :تلاعافتلا نم
ىرخأ عاونأو ،ىرخلأا ةيودلأا عم
تلاعافتلا
وأ يرطيبلا بيبطلا غلابإ كيلع ،ىرخأ
تارضحتسمو ىرخأ ةيودأ ا
ً
رخؤم ىقلت اذإ
.ىرخلأا ةيودلأا عم تلاعافتلا نع
ةجتانلا ةعجانلا مدع وأ رطاخملا بنجتل
يلديصلا
تاديوريتس :ىقلتي بلكلا ناك اذإ صاخ
لكشب يلديصلا وأ يرطيبلا بيبطلا غلابإ
كيلع
ذنم لقلأا ىلع ةعاس 24 راظتنلااب ىصوي(
باهتللال ةداضم ىرخأ تارضحتسمو
ىلكلا/لوبلا زاهج يف رثؤت ةيودأ
،)سكوكيڨيربب جلاعلا ءدب لبقو قباسلا
جلاعلا ءاهتنا
تانيتوربب طبترت ةيودأو ،)ريدختلل
ةيودأ ،ACE ميزنإ تاطبثم ،لوبلا تا
ّ
ردم :لاثم(
ةيودأ اهتفصب ةفورعم ةيودأ ءاطعإ هتاذ
تقولا يف متي نأ نع عانتملاا بجي .مدلا
.ىلكلل ةماس
،نزولا ضافخنا :ىلإ ءاودلا نم ةطرفم
ةعرج ءاطعإ يدؤي دق :ةطرفملا ةعرجلا
ينثلإا يف ةحرق ،غامدلا يف ررض ،)نهدلا
سدكت( دبكلا يف تارييغت ،ةيهشلا نادقف
اذإ .ءاودلا ءاطعإ فقو دعب ساكعنلال
لباق ضارعلأا هذه ضعب .ةافولاو تاؤيقت
،رشع
،اروف ءاودلا ءاطعإ فقو بجي ،ةطرفم ةعرج
ىلع تاملاع/ةملاع بلكلا ىدل ترهظ
.اروف يرطيبلا بيبطلا ةراشتساو
.فورعم ريغ :(
INCOMPATIBILITY ( ةمءلاملا صقن (
:نيزختلا تاميلعت
لوانتم نع ا
ً
ديعب ،قلغم ناكم يف ،رخآ ءاود
ّ
لكو ،ءاودلا اذه ظفح بجي !م
ّ
مستلا ب
ّ
نجت
.م
ّ
مستلا ب
ّ
نجتت اذكهو ،لافطلأا وأ/و دلاولأا ةيؤ
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
PREVICOX 57 MG AND 227 MG VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
PREVICOX 57 MG VETERINARY
PREVICOX 227 MG VETERINARY
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
TRADE NAME OF MEDICINAL PRODUCT:
ACTIVE SUBSTANCE:
PREVICOX 57 MG VETERINARY
Firocoxib 57 mg per chewable tablet
PREVICOX 227 MG VETERINARY
Firocoxib 227 mg per chewable tablet
EXCIPIENTS: Iron Oxides (E172) and Caramel (E150d).
For the full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM
Chewable tablets.
Tan-brown, round, convex, tablets with a cross-shaped break line on
one side. The tablets can
be divided into 2 or 4 equal parts.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
For the relief of pain and inflammation associated with osteoarthritis
in dogs.
For the relief of post-operative pain and inflammation associated with
soft-tissue surgery in
dogs.
For the relief of post-operative pain and inflammation associated with
orthopaedic and dental
surgery in dogs.
4.3 CONTRAINDICATIONS:
Do not use in pregnant or lactating bitches.
Do not use in animals less than 10 weeks of age or less than 3 kg body
weight.
Do not use in animals suffering from gastrointestinal bleeding, blood
dyscrasia or
haemorrhagic disorders.
Do not use concomitantly with corticosteroids or other non-steroidal
anti-inflammatory drugs
(NSAIDs).
4.4 SPECIAL WARNINGS: None.
4.5 SPECIAL PRECAUTIONS FOR USE:
Special precautions for use in animals: The recommended dose, see
section 4.9, should not be
exceeded.
Use in very young animals, or animals with suspected or confirmed
impairment of renal,
cardiac or hepatic function may involve additional risk. If such use
cannot be avoided, those
dogs require careful veterinary monitoring.
Page 2 of 6
Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there
is a potential risk of
increased renal toxicity. Concurrent administration of potentially
nephrotoxic drugs shou
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect arabă 20-12-2021
Prospect Prospect ebraică 20-12-2021

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor